Log in
Enquire now
‌

US Patent 9902741 Macrocyclic compounds as TRK kinase inhibitors

Patent 9902741 was granted and assigned to Array Biopharma Inc. on February, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Array Biopharma Inc.
Array Biopharma Inc.
Current Assignee
Array Biopharma Inc.
Array Biopharma Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9902741
Patent Inventor Names
Gabrielle R. Kolakowski0
Qian Zhao0
Steven W. Andrews0
Yutong Jiang0
Hong-Woon Yang0
Jeongbeob Seo0
Julia Haas0
Kevin Ronald Condroski0
Date of Patent
February 27, 2018
Patent Application Number
15632187
Date Filed
June 23, 2017
Patent Citations Received
‌
US Patent 12006306 Substituted pyridazines as TYK2 inhibitors
0
‌
US Patent 11878987 Heterocyclic compound as TRK inhibitor
0
Patent Primary Examiner
‌
Paul V Ward
Patent abstract

Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9902741 Macrocyclic compounds as TRK kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.